Pauels H G, Specht C, Becker C, Kölsch E
Institute for Immunology, University of Münster, Germany.
Scand J Immunol. 1996 Apr;43(4):421-30. doi: 10.1046/j.1365-3083.1996.d01-56.x.
The mechanisms of tolerance induction by tumour cells during early stages of tumourigenesis were analysed in a murine model system using the highly immunogenic BALB/c plasmacytoma ADJ-PC-5. Early stages of tumourigenesis were simulated in syngeneic BALB/c mice by repeated intraperitoneal injections with subimmunogenic doses of X-irradiated ADJ-PC-5 tumour cells. This treatment causes a state of tumour-specific tolerance in a high percentage of mice, involving a population of CD8+ peritoneal T cells which are able to suppress a protective tumour-specific Tc response against this tumour. Using a primary mixed lymphocyte tumour cell culture (MLTC) as an in vitro system to study suppressive mechanisms of such regulatory T cells, the role of production or consumption of a number of cytokines was analysed. The data presented here demonstrate that inhibition of a protective Tc response against ADJ-PC-5 tumour cells is due to IFN-gamma production by suppressive T cells from tolerized mice, but not to IL-2 consumption. In contrast to typical CD8+ Tc cells, ADJ-PC-5-specific CD8+ Tc cells do not produce IFN-gamma and are furthermore suppressed by IFN-gamma. Thus, tumour-induced suppressive T cells and tumour-specific Tc cells seem to represent functionally and phenotypically different subsets of CD8+ T cells, possibly pointing towards a differential activation of type-1 and type-2 CD8+ T cells depending on the dose of tumour cells.
利用具有高度免疫原性的BALB/c浆细胞瘤ADJ-PC-5,在小鼠模型系统中分析了肿瘤发生早期肿瘤细胞诱导耐受的机制。通过用亚免疫原剂量的X射线照射ADJ-PC-5肿瘤细胞对同基因BALB/c小鼠进行反复腹腔注射,模拟肿瘤发生的早期阶段。这种处理在高比例的小鼠中引起肿瘤特异性耐受状态,涉及一群能够抑制针对该肿瘤的保护性肿瘤特异性Tc反应的CD8+腹腔T细胞。使用原代混合淋巴细胞肿瘤细胞培养(MLTC)作为体外系统来研究此类调节性T细胞的抑制机制,分析了多种细胞因子产生或消耗的作用。此处呈现的数据表明,针对ADJ-PC-5肿瘤细胞的保护性Tc反应的抑制是由于来自耐受小鼠的抑制性T细胞产生IFN-γ,而不是由于IL-2的消耗。与典型的CD8+ Tc细胞不同,ADJ-PC-5特异性CD8+ Tc细胞不产生IFN-γ,并且还被IFN-γ抑制。因此,肿瘤诱导的抑制性T细胞和肿瘤特异性Tc细胞似乎代表了CD8+ T细胞在功能和表型上不同的亚群,这可能表明根据肿瘤细胞的剂量,1型和2型CD8+ T细胞存在差异激活。